Five New Research Programs to Receive Funding from the Samuel Waxman Cancer Research Foundation
Notice bibliographique
Résumé
Abstract The Samuel Waxman Cancer Research Foundation (SWCRF) is pleased to announce the funding of five new investigative teams from John Hopkins University, The University of Rochester Medical Center, The Salk Institute for Biological Studies, The University of New Mexico, and The Wistar Institute in Philadelphia. This brings the total worldwide members of the Institute Without Walls to 60. SWCRF is unique in that the research programs it supports are both cancer type-specific and concept-driven, and researchers must agree to collaborate with their SWCRF peers on research projects funded by the Foundation. This worldwide collaborative approach to cancer research is the guiding principle of the Foundation's "Institute Without Walls". Dr. Samuel Waxman, professor of medicine at New York's Mount Sinai Medical Center, and Founder and Scientific Director of the Foundation, stated: "We are very pleased to expand the scope of our cancer research activities with the funding of these additional five new research initiatives. We know these worthwhile projects, in collaboration with our collective efforts over the years, will continue to improve the treatment and outcome of cancer patients." Prospective research teams submitted 70 detailed proposals for this highly selective and competitive process. All proposals were peer-reviewed, assessing the merits of the work and the potential for collaborative programs in epigenetic therapy, tumor dormancy and cancer stem cells. The final grantees are determined by utilizing the NIH scoring system. All funded programs are reviewed annually by an independent, external committee of eminent scientists. The following new research programs are being funded by SWCRF in 2007: - "Targeting the Sumoylation Machinery for the Relief of Gene Silencing and Differentiation Therapy" - Dr. Frank Rauscher, The Wistar Institute, Philadelphia. This is a basic control of epigenetic components and a good target for cancer selective therapy. - "Novel Therapies Targeting Epigenetic Silencing of Tumor Suppressors" - Dr. Robert A. Casero, Jr., Johns Hopkins Kimmel Cancer Center, (Project Leader), Dr. Stephen B. Baylin, Johns Hopkins Kimmel Cancer Center; Dr. Steven Belinsky, Lovelace Respiratory Research Institute of the University of New Mexico. A specific epigenetic component that malfunctions in colorectal cancer has been identified and inhibitors are being tested in this program. - "Pharmacogenetic Targeting of the Nuclear Hormone Receptors PPARdelta/gamma in Colorectal Cancer" - Dr. Ronald Evans, HHMI and The Salk Institute for Biological Studies. The nuclear receptor family called PPAR plays an important role in inflammation thought to play an important role in the development of colon cancer. - "MicroRNAs Regulating Acute Leukemia" - Dr. Curt Civin, Johns Hopkins Kimmel Cancer Center. AND - "Differentiation Therapy and Epigenetic Modulation of Human Leukemia Stem Cells" - Dr. Craig Jordan, University of Rochester Medical Center. Dr. Civin and Dr. Jordan will collaborate with others in the SWCRF to understand how to reprogram leukemia stem cells and eliminate the root cause of acute leukemia. About the Samuel Waxman Cancer Research Foundation Now in its 32nd year, the Samuel Waxman Cancer Research Foundation (SWCRF) is a unique non-profit international organization dedicated to supporting focused concept-driven research to develop targeted cancer cell-specific therapies with minimal toxicity, such as differentiation therapy. Two drugs developed through Foundation-supported research, and now used worldwide, have proven the effectiveness of non-toxic differentiation in the treatment of acute promyelocytic leukemia (APL), which has helped cure 50,000 people. Since its inception, SWCRF has trained and supported more than 170 scientists with research grants exceeding $60 million. Based in New York City at The Mount Sinai Medical Center, the Foundation funds highly collaborative basic, translational and clinical research groups throughout the United States, Canada, China, Europe and Israel. SWCRF grant applicants are established investigators who agree to collaborate with other SWCRF investigators on research projects funded by the Foundation. Functioning as an "Institute Without Walls" the Foundation currently enables the collaboration of accomplished scientists in 35 different world-renown cancer research centers. SWCRF hosts international conferences that bring together differentiation therapy investigators in a major forum to share their findings with the scientific community. Foundation-supported projects are reviewed and evaluated annually by an independent external committee of eminent scientists. The Foundation derives most of its support from individual contributions. For more information, visit www.waxmancancer.org
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,003 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».